Biocon Limited (BIOCON) reported its Q2 FY27 results, showing a 2% increase in revenue to ₹4,423 Cr compared to ₹4,389 Cr in the same period last year. The company’s EBITDA margin, however, declined to 20% from 22% in Q2 FY26. The focus remains on translating growth into improved margins, free cash flow, debt reduction, and higher returns on capital.

Biosimilars Performance

The Biosimilars segment recorded revenue of ₹2,809 Cr, up 3% YoY. EBITDA stood at ₹623 Cr with a 22% margin. The segment’s performance was impacted by the timing of revenue recognition on certain shipments. The 10-year Pertuzumab partnership in Brazil provides long-term revenue visibility.

Generics Segment

The Generics segment saw a 10% YoY revenue growth to ₹774 Cr. EBITDA margin expanded by over 700bps YoY to 8%. Liraglutide is gaining traction across markets, strengthening the complex injectables portfolio.

Services Division

The Services division revenue stood at ₹833 Cr, up 13% QoQ. EBITDA margin improved by 500bps QoQ to 20%. The division expects further improvement in the second half of the fiscal year.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the Healthcare › Biotechnology sector. Here’s a quick read on where the business and the stock stand today.

Biocon drops 20.1% over three months and trades near its 52-week lows. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. RSI stands at 28, well into oversold territory. Yet sellers still dominated on 19 of recent sessions versus 11 for buyers, so the pressure has not fully lifted. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Alembic Pharmaceuticals Limited (APLLTD) reported its consolidated financial results for the second quarter and half year ended 30th September, 2026. The company delivered another quarter of strong, broad-based growth and improved profitability, reflecting consistent execution across markets. Revenue from operations increased by 36% year-on-year to Rs. 2603 Cr. Moreover, the Profit After Tax (PAT) surged by 81% year-on-year to Rs. 335 Cr.

Operational Highlights

The India Branded Business delivered 14% year-on-year growth, reaching Rs 725 Cr. in revenue for the quarter. Gynecology, Cardiology, Gastrology, and Ophthalmology registered robust growth. Animal Health continued its growth momentum with 23% growth for the quarter.

International Business

US Formulations grew by 77% to Rs. 1003 Cr. The company also had three launches in the US market during the quarter. Ex-US grew by 12% to Rs. 440 Cr. The Active Pharmaceutical Ingredients (API) business grew by 39% to Rs. 436 Cr.

Commenting on the results, Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said, “We delivered another quarter of strong, broad-based growth and improved profitability, reflecting consistent execution across markets. Following a strong first half, we are well positioned to sustain growth and create long-term value for all our stakeholders.”

For more information, visit www.alembicpharmaceuticals.com or contact Isha Lamba at +91 022-66951652 or isha.lamba@alembic.co.in.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alembic moves sideways over three months, with neither buyers nor sellers taking control. Thin margins at 8.9% leave limited room for error — any demand softness or cost spike hits the bottom line hard. Not a single revenue dip or loss quarter in five years — this is a business built to last through cycles. Buyers show up with 1.5x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. Revenue grows at 9.5% and profits at 25.4%, and the dividend yield stands at 1.51%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Alembic Pharmaceuticals Limited.

Dr. Lal Path Labs Ltd. (NSE: LALPATHLAB) showcased robust financial performance in Q2 FY27, marking a significant milestone with a 19.6% year-over-year revenue growth. The company’s profit after tax (PAT) surged by 27.5%, reflecting strong operational efficiency and strategic growth initiatives.

Financial Highlights

The financial results underscore the company’s resilience and growth momentum. Key financial metrics for Q2 FY27 include:

• Revenue: Rs. 874 crore, up 19.6% from Rs. 731 crore in Q2 FY26
• PAT: Rs. 194 crore, a 27.5% increase from Rs. 152 crore in Q2 FY26
• EBITDA: Rs. 280 crore, up 25.1% from Rs. 224 crore in Q2 FY26

Operational Excellence

The operational highlights of the quarter were driven by robust expansion across sample and patient volumes. The company’s focus on scientific excellence, network expansion, and tech-driven engagement has paid off, contributing to the overall growth.

Management Commentary

Mr. Ved Goel, Group CFO & CEO – International Business, remarked on the performance, stating: ‘We delivered a resilient performance in Q2 FY27, supported by healthy testing volumes, disciplined execution, and continued focus on operational excellence.’ He emphasized the company’s balanced approach to growth investments and profitability, highlighting the potential for long-term value creation.

Mr. Shankha Banerjee, Chief Executive Officer, added: ‘The healthcare ecosystem is increasingly embracing preventive and precision medicine, reinforcing the critical role of diagnostics in enabling timely clinical decisions.’ He noted the growing demand for specialized and high-complexity testing, driven by advancements in genomics, oncology, and other areas.

Hony. Brig Dr. Arvind Lal, Executive Chairman, emphasized the importance of screening and early detection in India’s public health infrastructure. He pointed out the increasing emphasis on reliable, high-quality confirmatory diagnostics and long-term disease monitoring, alongside the adoption of precision medicine and genomics.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Dr. Lal Path Labs Ltd.

Dr. Lal Path Labs Ltd. belongs to the Healthcare › Diagnostics & Research sector. Here’s a quick read on where the business and the stock stand today.

Dr. gains 24.9% over three months and trades near its 52-week highs. The PEG of 2.06 is on the high side. However, it is acceptable for a quality compounder with a strong moat. Revenue grows at 11.1% and profits at 28.3% CAGR. The market consistently rewards this kind of compounding. Buyers show up with 2.7x the volume of sellers. Moreover, they dominated on 17 of recent sessions versus 13 for sellers — a healthy accumulation pattern. The business grows revenue at 11.1% and profits at 28.3%, with D/E of 0.07. The stock reflects that strength. Moreover, when fundamentals and price action align, the PEG of 2.06 premium is usually justified. Check Fundamentals of Dr. Lal Path Labs Ltd..